From professional translators, enterprises, web pages and freely available translation repositories.
20 * amenorrhoea som følge af cancerbehandling udelukker ikke fødedygtighed.
counselling for women of childbearing potential, lenalidomide is contraindicated unless all of the following are met: • she understands the expected teratogenic risk to the unborn child • she understands the need for effective contraception, without interruption, 4 weeks before starting treatment, throughout the entire duration of treatment, and 4 weeks after the end of treatment • even if a woman of childbearing potential has amenorrhea she must follow all the advice on effective contraception
* amenorré som følge af cancerbehandling udelukker ikke muligheden for at blive gravid.
*amenorrhoea following cancer therapy does not rule out childbearing potential.
ctcae er en standardiseret klassificering af bivirkninger, som anvendes til vurdering af lægemidler til cancerbehandling.
the ctcae is a standardised classification of side effects used in assessing medicinal products for cancer therapy.
behandling med talimogen laherparepvec skal initieres og overvåges af en kvalificeret læge med erfaring inden for cancerbehandling.
treatment with talimogene laherparepvec should be initiated and supervised by a qualified physician experienced in the treatment of cancer.
caelyx kan, som andre doxorubicin hydrochlorid-præparater, potensere toksiciteten af anden cancerbehandling.
caelyx, like other doxorubicin hydrochloride preparations, may potentiate the toxicity of other anti-cancer therapies.
tumorlysesyndrom – metaboliske komplikationer, der kan forekomme under cancerbehandling og nogle gange endda uden behandling.
tumour lysis syndrome - metabolic complications that can occur during treatment of cancer and sometimes even without treatment.
onivyde (liposomal irinotecan) må kun ordineres og administreres af læger og sundhedspersonale med erfaring i cancerbehandling.
onivyde (liposomal irinotecan) must only be prescribed and administered to patients by healthcare professionals experienced in the use of anti-cancer therapies.
xy- genotype, turners syndrom, uterin agenesi. * amenorré som følge af cancerbehandling udelukker ikke muligheden for at blive gravid.
xy genotype, turner’ s syndrome, uterine agenesis. *amenorrhoea following cancer therapy does not rule out childbearing potential.
kliniske vejledninger af aggressiv behandling af diaré pga. cancerbehandling omfatter særlige rekommandationer om patientkommunikation, opmærksomhed og erkendelse af de tidlige tegn, anvendelse af midler mod diaré og antibiotika, ændringer i væskeindtag og diæt samt behov for hospitalsindlæggelse.
clinical guidelines describing the aggressive management of ctid includes specific recommendations on patient communication and awareness, recognition of early warning signs, use of anti-diarrhoeals and antibiotics, changes in fluid intake and diet, and need for hospitalization.
4 • xy- genotype, turner- syndrom, uterus- agenesi. * amenorrhoea som følge af cancerbehandling udelukker ikke fødedygtighed.
counselling for women of childbearing potential, lenalidomide is contraindicated unless all of the following are met: • she understands the expected teratogenic risk to the unborn child • she understands the need for effective contraception, without interruption, 4 weeks before starting treatment, throughout the entire duration of treatment, and 4 weeks after the end of treatment • even if a woman of childbearing potential has amenorrhea she must follow all the advice on effective contraception
kemoterapi (cancerbehandling), som er cytotoksisk (celledræbende), dræber også de hvide blodlegemer, hvilket kan føre til neutropeni (lavt antal hvide blodlegemer) og udvikling af infektioner.
chemotherapy (cancer treatment) that is cytotoxic (cell-killing) also kills white blood cells, which can lead to neutropenia (low white blood cell counts) and the development of infections.